Feasibility Pilot of AYA-PARTNER
Part of paid clinical trials in Chapel Hill, North Carolina.
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Study ID
- NCT07829146
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cancer
- Malignancies Multiple
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 39 Years
- Healthy Volunteers
- Not accepted
Interventions
- AYA-PARTNER Navigation Intervention — BEHAVIORALParticipants will receive personalized support and navigation from a trained study navigator for 4 months, with contact at least once each month through phone, text message, email, MyChart, or video based on their preference.
Study Details
This is a single-center, non-randomized feasibility pilot study of an adapted Adolescent and Young Adult Patient Advocacy, Real-Time Navigation, Equity and Reach (AYA-PARTNER) intervention for young adults ages 18-39 receiving systemic cancer treatment at the University of North Carolina at Chapel Hill (UNC) and UNC Rex and affiliated clinics. The study will use information from the electronic health record to identify young adults who may have unmet needs during cancer treatment. Examples include emergency or urgent care visits, missed appointments, no activation of the patient portal (MyChart), or treatment plans that may cause significant side effects. A trained study navigator will confirm eligibility, obtain informed consent, and provide personalized support for 4 months. The navigator will contact participants at least once each month by phone, text message, email, MyChart, or video, based on participant preference. Support may include connecting participants with supportive care services and sharing concerns with their oncology care team. The study will enroll 30 participants over 12 months, with a total study duration of 24 months. Participants will complete a needs assessment at the start of the study and again at 4 months, as well as a survey about their experience with the intervention at 4 months. The main goal of the study is to determine whether the intervention is feasible, measured by the percentage of participants who complete the 4-month survey. The study will consider the intervention feasible if at least 50% of participants complete the survey. Other goals are to determine how many eligible patients agree to participate and how acceptable the intervention is to patients and oncology clinicians. The study will also explore changes in participants' unmet needs and describe how the navigation program is delivered, including navigator activities, participant engagement, and other factors that may affect implementation.
Key Dates
- First listed
- Sep 18, 2026
- Start date
- Sep 15, 2026
- Status verified
- Sep 2026
- Primary completion
- Oct 31, 2027
- Completion
- Oct 31, 2027
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: AYA-PARTNERYoung adults between 18 and 39 years of age who are currently receiving systemic anti-cancer therapy or are expected to begin systemic anti-cancer therapy within a month.
Primary Outcome Measure
Feasibility of the AYA-PARTNER Intervention [ Time Frame: Up to 4 months ]
Central Contacts
- Hannah C Winslow919-984-0000
- Allison Bell
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | Jake Stein, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Chapel Hill, NC
Related Studies
- Study of the Effect of Innate on the Inflammatory Response to EndotoxinRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Research Triangle Park, North Carolina
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Pan Tumor Rollover StudyPHASE2 · Recruiting · Bristol-Myers Squibb · Louisville, Kentucky
- Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19Enrolling By Invitation · Duke University · Durham, North Carolina